Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auranofin Suppresses Cancer Cell Invasion by Inhibiting Heparanase-1 Expression via the aPKC-NF-κB Pathway.

International journal of molecular sciences·2026
Same author

Risk factors for adverse events or use of high-potency corticosteroids in non-infectious uveitis: a Japan claims database study (J-CAT2).

Immunological medicine·2026
Same author

Cell-cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer.

PloS one·2026
Same author

<i>GGT6</i> as a Prognostic Biomarker and Therapeutic Target in Melanoma Using an Information-theoretical Method.

Cancer genomics & proteomics·2026
Same author

Peptidomics and Beyond: Development of a Novel Platform Based on Capillary Electrophoresis-Mass Spectrometry for Metabolomics of Medium-Molecular-Weight Compounds.

Journal of proteome research·2026
Same author

Daily intake of cuminaldehyde-rich cumin essential oil improves cognitive function in healthy elderly Japanese adults: a randomized, double-blind, placebo-controlled pilot study.

Frontiers in nutrition·2026

Related Experiment Video

Updated: Jul 24, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer.

Taiki Okamoto1, Chotaro Onaga1, Izumi Matsuoka1

  • 1Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

Cancer Diagnosis & Prognosis
|July 5, 2023
PubMed
Summary

Solute carrier family 20 member 1 (SLC20A1) is elevated in prostate cancer, predicting poorer survival. Endocrine therapy is recommended for patients with high SLC20A1 expression.

Keywords:
Prostate cancerSLC20A1prognostic marker

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Experiment Videos

Last Updated: Jul 24, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Solute carrier family 20 member 1 (SLC20A1) high expression correlates with poor outcomes in breast cancer subtypes treated with endocrine therapy and radiotherapy.
  • The prognostic role of SLC20A1 in prostate cancer remains unclear.

Purpose of the Study:

  • To investigate the association between SLC20A1 expression and clinical outcomes in prostate cancer.
  • To evaluate the impact of endocrine therapy and radiotherapy on patients with high SLC20A1 expression.

Main Methods:

  • Analysis of open-source datasets including The Cancer Genome Atlas (TCGA) prostate and PanCancer Atlas.
  • Assessment of SLC20A1 expression in prostate cancer versus normal prostate tissue.
  • Kaplan-Meier and Cox regression analyses for survival and treatment effect evaluation.

Main Results:

  • SLC20A1 expression is significantly higher in prostate cancer tissues compared to normal tissues.
  • Elevated SLC20A1 expression is a predictor of poor disease-free and progression-free survival.
  • High SLC20A1 expression showed a trend towards poor outcomes after radiotherapy, but not after endocrine therapy.

Conclusions:

  • SLC20A1 demonstrates potential as a prognostic biomarker for prostate cancer.
  • Endocrine therapy may be the preferred treatment modality for prostate cancer patients with high SLC20A1 expression.